Pharma Focus Asia

Amphastar Receives FDA Approval for Regadenoson

Wednesday, May 25, 2022

Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Regadenoson injection, 0.08 mg/mL, 5mL Single Dose Pre-Filled Syringe. Regadenoson is indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The FDA determined that Amphastar's regadenoson is bioequivalent and therapeutically equivalent to Astellas Pharma U.S., Inc's Lexiscan® (Regadenoson Injection).

Amphastar's CEO and President, Dr. Jack Zhang, commented: "We are excited with the FDA's approval of our Regadenoson injection as this broadens our portfolio of products, highlighting our capabilities in combination product development, while providing patients and healthcare providers with another important option. Both the finished product and Active Pharmaceutical Ingredient (API) will be manufactured in the United States."

According to IQVIA, the U.S. sales for Astellas' Lexiscan® (Regadenoson Injection) were approximately $650 million for the 12 months that ended March 31, 2022.

The timing of commercialization of Amphastar's regadenoson product is subject to the confidential settlement terms agreed to between the Company, and Astellas US LLC.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024